Cargando…
Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers
The development of stereotactic body radiation therapy (SBRT) has revolutionized radiation therapy for lung cancers and is an emerging treatment option for pancreatic cancers. However, there are many questions on how to optimize its use in chemoradiotherapy. The most relevant addition to radiotherap...
Autores principales: | Hastak, Kedar, Bhutra, Steven, Parry, Renate, Ford, James M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432262/ https://www.ncbi.nlm.nih.gov/pubmed/28412751 http://dx.doi.org/10.18632/oncotarget.15464 |
Ejemplares similares
-
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells
por: Bridges, Kathleen A., et al.
Publicado: (2014) -
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
por: Vormoor, Britta, et al.
Publicado: (2014) -
Inhibitors of telomerase and poly(ADP-ribose) polymerases synergize to limit the lifespan of pancreatic cancer cells
por: Burchett, Katrina M., et al.
Publicado: (2017) -
Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888
por: Tuli, Richard, et al.
Publicado: (2014) -
Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies
por: Lesueur, Paul, et al.
Publicado: (2017)